keyword
MENU ▼
Read by QxMD icon Read
search

Xelox

keyword
https://www.readbyqxmd.com/read/29145602/genotype-based-selection-of-treatment-for-patients-with-advanced-colorectal-cancer-seticc-a-pharmacogenetic-based-randomized-phase-ii-trial
#1
A Abad, E Martínez-Balibrea, J M Viéitez, V A Orduña, P García Alfonso, J L Manzano, B Massutí, M Benavides, A Carrato, M Zanui, J Gallego, C Grávalos, V Conde, M Provencio, M Valladares, R Salazar, J Sastre, C Montagut, F Rivera, E Aranda
Background: There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3' untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy for patients with mCRC. Patients and methods: This randomized, open-label phase II trial compared bevacizumab plus XELOX (control) versus treatment tailored according to TYMS-3'UTR 6 bp ins/del and ERCC1-118C/T polymorphisms...
November 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29130233/-clinical-features-and-prognosis-analysis-of-21-gastric-cancer-patients-with-pathological-complete-response-after-neoadjuvant-chemotherapy
#2
Liangqun Peng, Wei Yang, Zhandong Zhang, Hongxing Liu, Yawei Hua
OBJECTIVE: To evaluate the clinical features and prognosis of gastric cancer patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). METHODS: Clinical data of 159 gastric cancer patients who received NAC followed by surgical resection between January 2012 and December 2014 at the Affiliated Tumor Hospital of Zhengzhou University were collected and clinical features of those with pCR were analyzed retrospectively. Kaplan-Meier method was used to estimate 3-year overall survival (OS) rate and recurrence-free survival (RFS) rate...
October 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29110729/penile-metastasis-from-rectal-adenocarcinoma-a-case-report
#3
Boubacar Efared, Gabrielle Atsame Ebang, Soufiane Tahirou, Layla Tahiri, Ibrahim Sory Sidibé, Fatimazahra Erregad, Aboubakry Sow, Nawal Hammas, Moulay H Farih, Laila Chbani, Hinde El Fatemi
BACKGROUND: Despite its rich vasculature, the penis is rarely involved by metastasis. Since the first description of penile metastasis in 1870, fewer than 500 cases have been reported in the literature. The pelvic organs are the main source of primary tumors that metastasize to the penis. CASE PRESENTATION: We report a case of a 46-year-old Arabic man who presented with erectile dysfunction and painful induration of the penile root. Eight months ago, he had undergone abdomino-perineal resection for rectal adenocarcinoma after neo-adjuvant chemotherapy...
November 6, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29065426/dihydropyrimidine-dehydrogenase-pharmacogenetics-for-predicting-fluoropyrimidine-related-toxicity-in-the-randomised-phase-iii-adjuvant-tosca-trial-in-high-risk-colon-cancer-patients
#4
RANDOMIZED CONTROLLED TRIAL
A Ruzzo, F Graziano, Fabio Galli, Francesca Galli, E Rulli, S Lonardi, M Ronzoni, B Massidda, V Zagonel, N Pella, C Mucciarini, R Labianca, M T Ionta, I Bagaloni, E Veltri, P Sozzi, S Barni, V Ricci, L Foltran, M Nicolini, E Biondi, A Bramati, D Turci, S Lazzarelli, C Verusio, F Bergamo, A Sobrero, L Frontini, M Menghi, M Magnani
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause reduced/abrogated DPD activity. DPYD variants analysis may help for defining individual patients' risk of fluoropyrimidine-related severe toxicity. METHODS: The TOSCA Italian randomised trial enrolled colon cancer patients for 3 or 6 months of either FOLFOX-4 or XELOX adjuvant chemotherapy. In an ancillary pharmacogenetic study, 10 DPYD variants (*2A rs3918290 G>A, *13 rs55886062 T>G, rs67376798 A>T, *4 rs1801158 G>A, *5 rs1801159 A>G, *6 rs1801160 G>A, *9A rs1801265 T>C, rs2297595 A>G, rs17376848 T>C, and rs75017182 C>G), were retrospectively tested for associations with ⩾grade 3 fluoropyrimidine-related adverse events (FAEs)...
October 24, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29041915/cost-effectiveness-analysis-of-xelox-versus-xelox-plus-bevacizumab-for-metastatic-colorectal-cancer-in-a-public-hospital-school
#5
Andrea Queiróz Ungari, Leonardo Régis Leira Pereira, Altacílio Aparecido Nunes, Fernanda Maris Peria
BACKGROUND: Metastatic colorectal cancer imposes a substantial burden on patients and society. Over the last years, progresses in the treatment have been made especially due to the introduction of monoclonal antibodies, such as bevacizumab which, on the other hand, has considerably increased the costs of treatment. We performed a cost-effectiveness analysis of bevacizumab plus XELOX in comparison with XELOX alone in metastatic colorectal cancer in first-line therapy, from the perspective of a public hospital school in Brazil...
October 17, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29040299/comparison-of-capecitabine-and-oxaliplatin-with-s-1-as-adjuvant-chemotherapy-in-stage-iii-gastric-cancer-after-d2-gastrectomy
#6
Jang Ho Cho, Jae Yun Lim, Jae Yong Cho
AIM: To compare capecitabine and oxaliplatin (XELOX) with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. METHODS: Clinical data from 206 patients who received XELOX or S-1 regimens as adjuvant chemotherapy in stage III gastric cancer were collected. Patients were divided into 2 groups according to regimen; the groups were XELOX (n = 114) and S-1 monotherapy (n = 92). RESULTS: 3-year disease-free survival (DFS) was higher in the S-1 group than in the XELOX group (66...
2017: PloS One
https://www.readbyqxmd.com/read/29032738/long-term-survival-in-a-patient-with-low-level-inflammatory-markers-and-liver-metastasis-converted-resectable-by-tace
#7
Malkhaz Mizandari, Natela Paksashvili, Nino Kikodze, Tamta Azrumelashvili, Ia Pantsulaia, Koba Shanava, Nona Janikashvili, Tinatin Chikovani
Case report presents the successful treatment of unresectable liver metastasis in a patient with colon cancer. A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon. 2 years later, a liver metastatic lesion was detected and had increased in size despite chemotherapy with capecitabine plus oxaliplatin (XELOX). Curative liver resection was conducted after conversion of unresectable tumor to resectable by transarterial chemoembolization followed by chemotherapy - irinotecan with fluorouracil and folinic acid (FOLFIRI)...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/28917648/challenges-of-conducting-a-prospective-clinical-trial-for-older-patients-lessons-learned-from-ncctg-n0949-alliance
#8
Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey
OBJECTIVES: While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ≥70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949. MATERIALS AND METHODS: We describe the conceptualization, development and limited results of N0949, a randomized phase III study of fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer...
September 13, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#9
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28900996/-clinicopathologic-characteristics-and-prognosis-of-gastric-hepatoid-adenocarcinoma
#10
Rongfei Zhao, Xinxin Wang, Xin Lan, Mingsen Li
OBJECTIVE: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). METHODS: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900499/profiling-chemotherapy-associated-myelotoxicity-among-chinese-gastric-cancer-population-receiving-cytotoxic-conventional-regimens-epidemiological-features-timing-predictors-and-clinical-impacts
#11
Ci Zhu, Yan Wang, Xicheng Wang, Chunmei Bai, Dan Su, Bing Cao, Jianming Xu
Objectives: We aim to evaluate the epidemiological features, timing, predictors and clinical impacts of chemotherapy-associated myelotoxicity in Chinese gastric cancer population receiving six established cytotoxic conventional regimens (CF/XP, EC(O)F/EC(O)X, DC(O)F/DC(O)X, PC(O)F/PC(O)X, FOLFOX4, or mFOLFOX7/XELOX). Patients and methods: A 4-year multicenter, prospective, observational study was conducted in multiple hospitals/institutes spanning three major regions in China. A total of 1,285 patients with gastric cancer, treated with six selected regimens between 2010 and 2014 were included...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28894576/first-line-chemotherapy-with-capecitabine-oxaliplatin-for-advanced-gastric-cancer-a-phase-i-study
#12
Hironaga Satake, Hisateru Yasui, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Masahito Kotaka, Takeshi Kato, Akihito Tsuji
Combination chemotherapy with capecitabine and oxaliplatin for gastric cancer (G-XELOX) is considered as a potentially promising regimen. However, the use of the G-XELOX regimen in Japanese patients has not been investigated to date, and recommended doses of G-XELOX for Japanese patients with metastatic gastric cancer have not been established. The aim of the present study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for systemic chemotherapy with G-XELOX for metastatic gastric cancer...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28874597/risk-of-febrile-neutropenia-associated-with-select-myelosuppressive-chemotherapy-regimens-in-a-large-community-based-oncology-practice
#13
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H Page, Chun Chao
Background: NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based primarily on clinical trial evidence. Many chemotherapy regimens, however, remain unclassified by NCCN or lack FN incidence data in real-world clinical practice. Patients and Methods: We evaluated incidence proportions of FN and grade 4 and 3/4 neutropenia during the first chemotherapy course among patients from Kaiser Permanente Southern California who received selected chemotherapy regimens without well-established FN risk...
September 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28860808/monocyte-to-lymphocyte-ratio-predicts-survival-in-patients-with-advanced-gastric-cancer-undergoing-neoadjuvant-chemotherapy
#14
Li Chen, Ying Hao, Lihua Zhu, Sen Li, Yanjiao Zuo, Yuxin Zhang, Hongjiang Song, Yingwei Xue
BACKGROUND: Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of the monocyte to lymphocyte ratio (MLR) in patients with advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) neoadjuvant chemotherapy regimen. METHODS: The data from Harbin Medical University Cancer Hospital from August 2008 to September 2015 were retrospectively collected...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28766482/self-reported-adherence-to-capecitabine-on-xelox-treatment-as-adjuvant-therapy-for-colorectal-cancer
#15
Kazuyoshi Kawakami, Takashi Yokokawa, Kazuo Sugita, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Kensei Yamaguchi, Ayaka Inoue, Yoshiaki Machida, Toshiharu Yamaguchi, Toshihiro Hama
Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as adjuvant therapy for colorectal cancer. The main aim of this study was to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011 and April 30, 2015 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research...
August 1, 2017: Oncology Research
https://www.readbyqxmd.com/read/28687001/clinical-efficacy-of-neoadjuvant-chemotherapy-regimens-fleeox-vs-xelox-in-patients-with-initially-unresectable-advanced-gastric-cancer-a-propensity-score-analysis
#16
Yang Li, Jun Chen, Qi He, Xiang Ji, Xulin Wang, Chaogang Fan, Guoli Li
PURPOSE: This study was designed to assess the effectiveness of FLEEOX (5-Fu, leucovorin, etoposide, oxaliplatin, and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as neoadjuvant chemotherapy (NAC) for initially unresectable advanced gastric cancer (AGC). METHODS: This study reviewed patients who underwent FLEEOX or XELOX for initially unresectable AGC. To reduce the bias in patient selection, we conducted propensity score match (PSM) with 1:1 ratio...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28668898/clinical-study-on-the-medical-value-of-combination-therapy-involving-adoptive-immunotherapy-and-chemotherapy-for-stage-iv-colorectal-cancer-comvi-study
#17
Yoichiro Yoshida, Masayasu Naito, Teppei Yamada, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Gotoh, Shohta Kodama, Yuichi Yamashita, Suguru Hasegawa
BACKGROUND: Adoptive immunotherapy for cancer has evolved through development of novel technologies for generating a large number of activated killer cells, such as αβ T-cells, γδ T-cells, and natural killer cells. There has been no prospective trial of combination therapy involving adoptive immunotherapy and first-line chemotherapy for stage IV colorectal cancer. The present pilot study aimed to evaluate the safety and feasibility of combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer (COMVI study)...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668897/hepatectomy-for-liver-metastases-of-colorectal-cancer-after-adoptive-chemoimmunotherapy-using-activated-%C3%AE-%C3%AE-t-cells
#18
Fuminori Ishii, Yoichiro Yoshida, Yasushi Yamauchi, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Daisuke Kato, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Goto, Yoshihiro Hamada, Satoshi Nimura, Shohta Kodama, Suguru Hasegawa
BACKGROUND/AIM: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. PATIENTS AND METHODS: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668863/phase-i-study-of-neoadjuvant-chemotherapy-with-capecitabine-and-oxaliplatin-for-locally-advanced-gastric-cancer
#19
Hironaga Satake, Masato Kondo, Motoko Mizumoto, Takeshi Kotake, Yoshihiro Okita, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Akira Miki, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
AIM: To determine the recommended dose of neoadjuvant chemotherapy of combined capecitabine and oxalipatin (G-XELOX) for locally advanced gastric cancer. PATIENTS AND METHODS: Patients received two cycles of neoadjuvant chemotherapy with oxaliplatin on day 1 and capecitabine (2,000 mg/m(2)/day, b.i.d.) on days 1-14, repeated every 3 weeks. They then underwent gastrectomy with curative D2/3 lymph-node dissection followed by adjuvant therapy with S-1 for 1 year. De-escalation of oxaliplatin dose was planned (starting at level 1, oxalipatin 130 mg/m(2))...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28599498/sequential-administration-of-xelox-and-xeliri-is-effective-feasible-and-well-tolerated-by-patients-with-metastatic-colorectal-cancer
#20
Taro Fukui, Koichi Suzuki, Kosuke Ichida, Yuji Takayama, Nao Kakizawa, Yuta Muto, Fumi Hasegawa, Fumiaki Watanabe, Rina Kikugawa, Masaaki Saito, Shingo Tsujinaka, Yasuyuki Miyakura, Toshiki Rikiyama
Sequential administration of the chemotherapy regimes capecitabine and oxaliplatin (XELOX) and capecitabine and irinotecan (XELIRI) in the first- to second-line treatment setting would allow patients to be managed more easily in an outpatient unit. However, a small number of studies have raised concerns of cumulative adverse events as a consequence of the continuous use of capecitabine. To investigate this, the present study conducted a retrospective review of 81 consecutive metastatic colorectal cancer (mCRC) patients treated with the oxaliplatin, fluorouracil and leucovorin-irinotecan, fluorouracil and leucovorin (FOLFOX-FOFIRI/F-F) regimen (n=40) or the XELOX-XELIRI (X-X) regimen (n=41) in first- to second-line chemotherapy in Saitama Medical Center between 2006 and 2012...
June 2017: Oncology Letters
keyword
keyword
2278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"